Mallinckrodt Plc Ordinary Share (MNK) 122.01 $MNK
3 Best Stocks for Investing in Generic Drugs
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 25, 11:02AM CDT
Source: FoolEditorial on Flickr. Americans spent more on prescription drugs last year than ever before -- nearly $374 billion, according to IMS Health . That figure reflected a 13.1% jump over 2013 spending. Health insurers and government...
MNK: 122.01 (-2.84), ACT: 295.41 (-2.95), AKRX: 55.24 (-0.68)
Teva-Active Biotech Start Phase II on MS Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:37PM CDT
Teva Pharmaceutical Industries Ltd. (TEVA) and Active Biotech started patient enrollment in a phase II study on laquinimod for primary progressive multiple sclerosis.
MNK: 122.01 (-2.84), TEVA: 64.41 (+1.16), MNTA: 20.13 (+0.04), NVS: 104.28 (-1.22)
Preview: European Investors Still In Love With North American Equities
Garry Wilson - at Seeking Alpha - Thu Apr 23, 11:41AM CDT
CNX: 30.20 (-0.48), PRGO: 192.89 (-8.74), CAM: 52.81 (+0.03), MKC: 75.84 (-0.38), MON: 118.46 (+0.97), KORS: 63.48 (+0.14), RL: 136.47 (-0.90), DLPH: 83.51 (+0.32), MSI: 60.57 (-0.27), DO: 29.82 (-0.58), MAT: 30.20 (+1.28), NWL: 39.54 (-0.08), THC: 50.65 (-0.58), DNR: 8.10 (-0.31), MA: 90.72 (-0.16), MNK: 122.01 (-2.84), HAR: 145.10 (-1.39), HES: 75.21 (-0.59), PBI: 22.91 (-0.26), UHS: 122.69 (+0.09), EW: 138.33 (-3.59), MHFI: 106.23 (+0.97), CELG: 118.71 (+2.62), MCO: 107.50 (-0.26), MS: 37.36 (-0.02), SYMC: 24.67 (+0.03), UA: 82.56 (-0.70), NTRS: 73.10 (-0.69), ESV: 24.04 (-0.23), SIAL: 139.00 (+0.03), ESS: 227.01 (-0.74), XRAY: 52.42 (+0.30), CTSH: 59.73 (-1.47), NE: 15.67 (-0.40), KMI: 44.34 (-0.23), KEY: 14.23 (-0.11), ADBE: 76.54 (+0.02), KIM: 25.43 (+0.23), PPG: 223.31 (-2.57), APD: 150.06 (-0.54), EMN: 75.47 (+0.17), CF: 294.44 (+4.67), LRCX: 76.70 (-0.38), TSO: 89.63 (+3.13), RHT: 76.83 (-0.02), GM: 35.59 (-0.33), KLAC: 58.89 (-0.96), CELGZ: 2.76 (-0.12), CRM: 67.83 (-0.64)
Mallinckrodt To Present At Deutsche Bank Healthcare Conference
PR Newswire - Wed Apr 22, 4:00PM CDT
Mallinckrodt plc (NYSE: MNK), a leading specialty biopharmaceutical company, will present on Wednesday, May 6, 2015, at the Deutsche Bank 40th Annual Health Care Conference at the InterContinental Boston hotel in Boston, Mass.
MNK: 122.01 (-2.84), DB: 34.26 (+0.11)
Akorn Leads Top Generic-Drug Stocks, Nears Buy Point
at Investor's Business Daily - Mon Apr 20, 5:06PM CDT
The generic-drug group was ranked No. 2 out of the 197 industries tracked by IBD on Monday, so it's little wonder that three of its members made the 16-stock Spotlight screen. Akorn (AKRX), arguably the top stock in the industry, is nearing a 55.96...
MNK: 122.01 (-2.84), LCI: 67.40 (unch), AKRX: 55.24 (-0.68)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 4:36PM CDT
MNK: 122.01 (-2.84), FARO: 43.44 (-1.22), MDVN: 131.01 (-1.50), CRIS: 2.96 (-0.01), E: 36.82 (-0.26), PH: 122.49 (-0.94), YOKU: 17.03 (+0.12), FXCM: 2.08 (-0.03), VSLR: 14.50 (-0.20), IGT: 20.21 (+0.21)
Novartis and Momenta Get FDA Nod For Generic Copaxone - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 4:10PM CDT
Novartis AG (NVS) announced that its generic arm has received FDA approval for Glatopa, the first generic version of Teva Pharmaceuticals' (TEVA) multiple sclerosis drug, Copaxone.
MNK: 122.01 (-2.84), TEVA: 64.41 (+1.16), MNTA: 20.13 (+0.04), NVS: 104.28 (-1.22)
Pacira Down on Subpoena on Exparel Marketing Issues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 3:10PM CDT
Shares of Pacira Pharmaceuticals, Inc. (PCRX) were down 9.6% after the company received a subpoena from the U.S. Department of Justice, U.S. Attorney's Office for the District of New Jersey.
MNK: 122.01 (-2.84), VRX: 210.42 (+1.03), ARQL: 2.12 (unch), PCRX: 85.07 (+0.80)
Mallinckrodt completes Ikaria buy
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 7:11AM CDT
MNK: 122.01 (-2.84)
Mallinckrodt acquires Ikaria for about USD2.3bn in cash
M2 - Fri Apr 17, 6:10AM CDT
Biopharmaceutical company Mallinckrodt (NYSE:MNK) revealed on Thursday that it has completed the acquisition of Ikaria for a purchase price of about USD2.3bn in all-cash transaction.
MNK: 122.01 (-2.84)
Mallinckrodt Completes Acquisition Of Ikaria
PR Newswire - Thu Apr 16, 3:15PM CDT
Mallinckrodt plc (NYSE: MNK), a leading specialty biopharmaceutical company, today announced that it has completed its acquisition of Ikaria, Inc. at a purchase price of approximately $2.3 billion. The Ikaria acquisition extends Mallinckrodt's footprint in the hospital market and expands its reach into neonatal critical care with INOMAX® (inhaled nitric oxide), a vital treatment option for a highly vulnerable patient population. It also accelerates Mallinckrodt's rapid growth in specialty brands -- adding significant portfolio diversity with a high-value, high-margin integrated drug-device-service product offering.
MNK: 122.01 (-2.84)
Roche Collaborates with Astellas Pharma for Tissue Diagnostics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 5:22PM CDT
Roche Holding Ag (RHHBY) announced that its member company, Ventana Medical Systems, Inc. has entered into a master collaboration agreement with Japan-based Astellas Pharma Inc. (ALPMY).
MNK: 122.01 (-2.84), VRX: 210.42 (+1.03)
Abbott Labs, Sekisui Medical to Offer Coagulation Tests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 5:06PM CDT
Abbott Laboratories (ABT) announced that it has entered into an agreement with Sekisui Medical to offer coagulation testing solutions for laboratories on a worldwide basis.
MNK: 122.01 (-2.84), ABT: 48.32 (-0.14), VRX: 210.42 (+1.03), ABBV: 66.07 (+1.82)
Mallinckrodt Pharmaceuticals to Sponsor the National Kidney Foundation Kidney Walk
GlobeNewswire - Tue Apr 14, 3:00PM CDT
Mallinckrodt Pharmaceuticals (NYSE:MNK) has been named National Corporate Sponsor for the 2015 Kidney Walk and will sponsor 100 Kidney Walk events in major U.S. cities as part of its support of the National Kidney Foundation (NKF).
MNK: 122.01 (-2.84)
Roche Acquires CAPP Medical to Strengthen Cancer Diagnosis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 1:37PM CDT
Roche Holding AG (RHHBY) announced that it has acquired privately-held genomics research company, CAPP Medical.
MNK: 122.01 (-2.84), VRX: 210.42 (+1.03), ARQL: 2.12 (unch)
Pacira Announces Encouraging Data on Lead Drug Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 4:11PM CDT
Pacira Pharmaceuticals Inc. (PCRX) announced encouraging new data from a study conducted on its lead drug Exparel by the University Of Illinois College Of Medicine.
MNK: 122.01 (-2.84), VRX: 210.42 (+1.03), ARQL: 2.12 (unch), PCRX: 85.07 (+0.80)
Casey's General Store, MercadoLibre, Valero Energy, Mallinckrodt and Marathon Petroleum highlighted as Zacks Bull and Bear of the Day - Press Releases
Zacks Equity Research - Zacks Investment Research - Fri Apr 10, 8:30AM CDT
Casey's General Store, MercadoLibre, Valero Energy, Mallinckrodt and Marathon Petroleum highlighted as Zacks Bull and Bear of the Day
MNK: 122.01 (-2.84), VLO: 60.05 (+0.82), MPC: 103.15 (+1.46), MELI: 137.48 (-1.49), CASY: 85.80 (-0.02)
Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace
at The Street - Fri Apr 10, 6:15AM CDT
The recent bid by Mylan to acquire Perrigo offers the latest example of pharma companies that have been seeking growth opportunities.
MNK: 122.01 (-2.84), AGN: 240.22 (+2.88), VRX: 210.42 (+1.03), PRGO: 192.89 (-8.74), ACT: 295.41 (-2.95), COV: 106.71 (-1.36), SLXP: 172.96 (+0.15), HZNP: 31.75 (+0.97), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16)
Jim Cramer's 'Mad Money' Recap: Ignore the Chatter, Stick With Best-of-Breed Stocks
at The Street - Thu Apr 09, 7:28PM CDT
Many investors are getting caught up in the takeover speculation game, Cramer warns. Don't do it.
MNK: 122.01 (-2.84), VRX: 210.42 (+1.03), ACT: 295.41 (-2.95), GE: 26.80 (-0.05), TERP: 41.68 (-0.38), SPG: 188.71 (-0.35), IMGN: 9.96 (-0.29), MYL: 76.06 (+2.37), MO: 52.07 (-0.28), VTR: 72.82 (-0.24), RAD: 8.25 (-0.01), SBUX: 51.84 (+2.41), UA: 82.56 (-0.70), T: 34.01 (-0.22), PM: 82.75 (-0.80), AA: 13.22 (+0.03), RIG: 16.40 (-0.57), SUNE: 26.61 (-0.89), HZNP: 31.75 (+0.97), AAL: 52.71 (+1.26), COST: 148.12 (+0.82), TWTR: 50.82 (-0.59), MAC: 83.23 (+0.89), WTW: 8.25 (+0.15)
3 Top-Ranked Stocks Likely to Beat Earnings This Quarter - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 3:36PM CDT
Use the Zacks' Earnings ESP system to discover the winners of this earnings season before they report.
MNK: 122.01 (-2.84), VLO: 60.05 (+0.82), MPC: 103.15 (+1.46)
3 Best Stocks for Investing in Generic Drugs
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 25, 11:02AM CDT
Source: FoolEditorial on Flickr. Americans spent more on prescription drugs last year than ever before -- nearly $374 billion, according to IMS Health . That figure reflected a 13.1% jump over 2013 spending. Health insurers and government...
MNK: 122.01 (-2.84), ACT: 295.41 (-2.95), AKRX: 55.24 (-0.68)
Teva-Active Biotech Start Phase II on MS Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:37PM CDT
Teva Pharmaceutical Industries Ltd. (TEVA) and Active Biotech started patient enrollment in a phase II study on laquinimod for primary progressive multiple sclerosis.
MNK: 122.01 (-2.84), TEVA: 64.41 (+1.16), MNTA: 20.13 (+0.04), NVS: 104.28 (-1.22)
Preview: European Investors Still In Love With North American Equities
Garry Wilson - at Seeking Alpha - Thu Apr 23, 11:41AM CDT
CNX: 30.20 (-0.48), PRGO: 192.89 (-8.74), CAM: 52.81 (+0.03), MKC: 75.84 (-0.38), MON: 118.46 (+0.97), KORS: 63.48 (+0.14), RL: 136.47 (-0.90), DLPH: 83.51 (+0.32), MSI: 60.57 (-0.27), DO: 29.82 (-0.58), MAT: 30.20 (+1.28), NWL: 39.54 (-0.08), THC: 50.65 (-0.58), DNR: 8.10 (-0.31), MA: 90.72 (-0.16), MNK: 122.01 (-2.84), HAR: 145.10 (-1.39), HES: 75.21 (-0.59), PBI: 22.91 (-0.26), UHS: 122.69 (+0.09), EW: 138.33 (-3.59), MHFI: 106.23 (+0.97), CELG: 118.71 (+2.62), MCO: 107.50 (-0.26), MS: 37.36 (-0.02), SYMC: 24.67 (+0.03), UA: 82.56 (-0.70), NTRS: 73.10 (-0.69), ESV: 24.04 (-0.23), SIAL: 139.00 (+0.03), ESS: 227.01 (-0.74), XRAY: 52.42 (+0.30), CTSH: 59.73 (-1.47), NE: 15.67 (-0.40), KMI: 44.34 (-0.23), KEY: 14.23 (-0.11), ADBE: 76.54 (+0.02), KIM: 25.43 (+0.23), PPG: 223.31 (-2.57), APD: 150.06 (-0.54), EMN: 75.47 (+0.17), CF: 294.44 (+4.67), LRCX: 76.70 (-0.38), TSO: 89.63 (+3.13), RHT: 76.83 (-0.02), GM: 35.59 (-0.33), KLAC: 58.89 (-0.96), CELGZ: 2.76 (-0.12), CRM: 67.83 (-0.64)
Mallinckrodt To Present At Deutsche Bank Healthcare Conference
PR Newswire - Wed Apr 22, 4:00PM CDT
Mallinckrodt plc (NYSE: MNK), a leading specialty biopharmaceutical company, will present on Wednesday, May 6, 2015, at the Deutsche Bank 40th Annual Health Care Conference at the InterContinental Boston hotel in Boston, Mass.
MNK: 122.01 (-2.84), DB: 34.26 (+0.11)
Akorn Leads Top Generic-Drug Stocks, Nears Buy Point
at Investor's Business Daily - Mon Apr 20, 5:06PM CDT
The generic-drug group was ranked No. 2 out of the 197 industries tracked by IBD on Monday, so it's little wonder that three of its members made the 16-stock Spotlight screen. Akorn (AKRX), arguably the top stock in the industry, is nearing a 55.96...
MNK: 122.01 (-2.84), LCI: 67.40 (unch), AKRX: 55.24 (-0.68)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 4:36PM CDT
MNK: 122.01 (-2.84), FARO: 43.44 (-1.22), MDVN: 131.01 (-1.50), CRIS: 2.96 (-0.01), E: 36.82 (-0.26), PH: 122.49 (-0.94), YOKU: 17.03 (+0.12), FXCM: 2.08 (-0.03), VSLR: 14.50 (-0.20), IGT: 20.21 (+0.21)
Novartis and Momenta Get FDA Nod For Generic Copaxone - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 4:10PM CDT
Novartis AG (NVS) announced that its generic arm has received FDA approval for Glatopa, the first generic version of Teva Pharmaceuticals' (TEVA) multiple sclerosis drug, Copaxone.
MNK: 122.01 (-2.84), TEVA: 64.41 (+1.16), MNTA: 20.13 (+0.04), NVS: 104.28 (-1.22)
Pacira Down on Subpoena on Exparel Marketing Issues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 3:10PM CDT
Shares of Pacira Pharmaceuticals, Inc. (PCRX) were down 9.6% after the company received a subpoena from the U.S. Department of Justice, U.S. Attorney's Office for the District of New Jersey.
MNK: 122.01 (-2.84), VRX: 210.42 (+1.03), ARQL: 2.12 (unch), PCRX: 85.07 (+0.80)
Mallinckrodt completes Ikaria buy
Seeking Alpha - at Seeking Alpha - Fri Apr 17, 7:11AM CDT
MNK: 122.01 (-2.84)
Mallinckrodt acquires Ikaria for about USD2.3bn in cash
M2 - Fri Apr 17, 6:10AM CDT
Biopharmaceutical company Mallinckrodt (NYSE:MNK) revealed on Thursday that it has completed the acquisition of Ikaria for a purchase price of about USD2.3bn in all-cash transaction.
MNK: 122.01 (-2.84)
Mallinckrodt Completes Acquisition Of Ikaria
PR Newswire - Thu Apr 16, 3:15PM CDT
Mallinckrodt plc (NYSE: MNK), a leading specialty biopharmaceutical company, today announced that it has completed its acquisition of Ikaria, Inc. at a purchase price of approximately $2.3 billion. The Ikaria acquisition extends Mallinckrodt's footprint in the hospital market and expands its reach into neonatal critical care with INOMAX® (inhaled nitric oxide), a vital treatment option for a highly vulnerable patient population. It also accelerates Mallinckrodt's rapid growth in specialty brands -- adding significant portfolio diversity with a high-value, high-margin integrated drug-device-service product offering.
MNK: 122.01 (-2.84)
Roche Collaborates with Astellas Pharma for Tissue Diagnostics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 5:22PM CDT
Roche Holding Ag (RHHBY) announced that its member company, Ventana Medical Systems, Inc. has entered into a master collaboration agreement with Japan-based Astellas Pharma Inc. (ALPMY).
MNK: 122.01 (-2.84), VRX: 210.42 (+1.03)
Abbott Labs, Sekisui Medical to Offer Coagulation Tests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 5:06PM CDT
Abbott Laboratories (ABT) announced that it has entered into an agreement with Sekisui Medical to offer coagulation testing solutions for laboratories on a worldwide basis.
MNK: 122.01 (-2.84), ABT: 48.32 (-0.14), VRX: 210.42 (+1.03), ABBV: 66.07 (+1.82)
Mallinckrodt Pharmaceuticals to Sponsor the National Kidney Foundation Kidney Walk
GlobeNewswire - Tue Apr 14, 3:00PM CDT
Mallinckrodt Pharmaceuticals (NYSE:MNK) has been named National Corporate Sponsor for the 2015 Kidney Walk and will sponsor 100 Kidney Walk events in major U.S. cities as part of its support of the National Kidney Foundation (NKF).
MNK: 122.01 (-2.84)
Roche Acquires CAPP Medical to Strengthen Cancer Diagnosis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 1:37PM CDT
Roche Holding AG (RHHBY) announced that it has acquired privately-held genomics research company, CAPP Medical.
MNK: 122.01 (-2.84), VRX: 210.42 (+1.03), ARQL: 2.12 (unch)
Pacira Announces Encouraging Data on Lead Drug Exparel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 4:11PM CDT
Pacira Pharmaceuticals Inc. (PCRX) announced encouraging new data from a study conducted on its lead drug Exparel by the University Of Illinois College Of Medicine.
MNK: 122.01 (-2.84), VRX: 210.42 (+1.03), ARQL: 2.12 (unch), PCRX: 85.07 (+0.80)
Casey's General Store, MercadoLibre, Valero Energy, Mallinckrodt and Marathon Petroleum highlighted as Zacks Bull and Bear of the Day - Press Releases
Zacks Equity Research - Zacks Investment Research - Fri Apr 10, 8:30AM CDT
Casey's General Store, MercadoLibre, Valero Energy, Mallinckrodt and Marathon Petroleum highlighted as Zacks Bull and Bear of the Day
MNK: 122.01 (-2.84), VLO: 60.05 (+0.82), MPC: 103.15 (+1.46), MELI: 137.48 (-1.49), CASY: 85.80 (-0.02)
Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace
at The Street - Fri Apr 10, 6:15AM CDT
The recent bid by Mylan to acquire Perrigo offers the latest example of pharma companies that have been seeking growth opportunities.
MNK: 122.01 (-2.84), AGN: 240.22 (+2.88), VRX: 210.42 (+1.03), PRGO: 192.89 (-8.74), ACT: 295.41 (-2.95), COV: 106.71 (-1.36), SLXP: 172.96 (+0.15), HZNP: 31.75 (+0.97), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16)
Jim Cramer's 'Mad Money' Recap: Ignore the Chatter, Stick With Best-of-Breed Stocks
at The Street - Thu Apr 09, 7:28PM CDT
Many investors are getting caught up in the takeover speculation game, Cramer warns. Don't do it.
MNK: 122.01 (-2.84), VRX: 210.42 (+1.03), ACT: 295.41 (-2.95), GE: 26.80 (-0.05), TERP: 41.68 (-0.38), SPG: 188.71 (-0.35), IMGN: 9.96 (-0.29), MYL: 76.06 (+2.37), MO: 52.07 (-0.28), VTR: 72.82 (-0.24), RAD: 8.25 (-0.01), SBUX: 51.84 (+2.41), UA: 82.56 (-0.70), T: 34.01 (-0.22), PM: 82.75 (-0.80), AA: 13.22 (+0.03), RIG: 16.40 (-0.57), SUNE: 26.61 (-0.89), HZNP: 31.75 (+0.97), AAL: 52.71 (+1.26), COST: 148.12 (+0.82), TWTR: 50.82 (-0.59), MAC: 83.23 (+0.89), WTW: 8.25 (+0.15)
3 Top-Ranked Stocks Likely to Beat Earnings This Quarter - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 3:36PM CDT
Use the Zacks' Earnings ESP system to discover the winners of this earnings season before they report.
MNK: 122.01 (-2.84), VLO: 60.05 (+0.82), MPC: 103.15 (+1.46)
